A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume 11, Issue 3, Pages 296-304
Publisher
Wiley
Online
2018-01-20
DOI
10.1111/cts.12535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
- (2016) Min Zhu et al. CLINICAL PHARMACOKINETICS
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
- (2015) Gurunadh R. Chichili et al. Science Translational Medicine
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
- (2014) Herbert Struemper et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
- (2013) Peter J.K. van Meer et al. mAbs
- Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
- (2012) Jing Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
- (2011) Rong Deng et al. mAbs
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus
- (2009) Paweł Wiczling et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
- (2009) Rafael Ponce et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More